Figini M, Ferri R, Mezzanzanica D, Bagnoli M, Luison E, Miotti S, Canevari S
Department of Experimental Oncology, Unit of Molecular Therapies, Istituto Nazionale Tumori, Via Venezian 1, 20133 Milan, Italy.
Gene Ther. 2003 Jun;10(12):1018-25. doi: 10.1038/sj.gt.3301962.
The alpha-folate receptor (FR) is selectively overexpressed in 90% of nonmucinous ovarian carcinomas, whereas no expression is detectable in normal ovarian surface epithelium (OSE). Indirect evidence suggests that FR expression is associated with tumor progression and affects cell proliferation. To evaluate better the role of FR, we developed an approach based on intracellular expression of single-chain (sc) antibodies (intrabody) to downmodulate membrane expression of FR in ovary cancer cells. IGROV-1 and SKOV3 ovarian carcinoma cell lines were transfected with an anti-FR intrabody. Transfectants and parental cells were tested for FR, integrins and anti-FR intrabody expression by fluorescence-activated cell sorting (FACS), reverse transcription and polymerase chain reaction (RT-PCR) and/or immunoblotting. Cell growth characteristics and adhesion properties were evaluated in liquid, semisolid and organotypic cultures. The anti-FR scFv inhibited FR expression from 60 to 99%. At physiological concentrations of folate, proliferation varied directly as a function of FR expression. FR downmodulation was accompanied by reduced colony-forming ability in soft agar, morphological change of the cells, significant enhanced adhesion to laminin or Matrigel, a two- to three-fold increase in alpha6beta4 integrin expression, and a marked reduction in laminin production. In three-dimensional organotypic cultures, anti-FR intrabody-transfected IGROV1 cells grew as a single-ordered layer, reminiscent of normal OSE growth in vivo. In conclusion, the anti-FR intrabody reverses the transformed phenotype in ovary cancer cells and may provide an efficient means to inhibit selectively the growth of these cells.
α-叶酸受体(FR)在90%的非黏液性卵巢癌中选择性过表达,而在正常卵巢表面上皮(OSE)中未检测到表达。间接证据表明,FR表达与肿瘤进展相关并影响细胞增殖。为了更好地评估FR的作用,我们开发了一种基于单链(sc)抗体(细胞内抗体)细胞内表达的方法,以下调卵巢癌细胞中FR的膜表达。用抗FR细胞内抗体转染IGROV-1和SKOV3卵巢癌细胞系。通过荧光激活细胞分选(FACS)、逆转录和聚合酶链反应(RT-PCR)和/或免疫印迹法检测转染子和亲本细胞的FR、整合素和抗FR细胞内抗体表达。在液体、半固体和器官型培养中评估细胞生长特性和黏附特性。抗FR单链抗体(scFv)抑制FR表达60%至99%。在生理浓度的叶酸条件下,增殖与FR表达直接相关。FR下调伴随着软琼脂中集落形成能力降低、细胞形态变化、对层粘连蛋白或基质胶的黏附显著增强、α6β4整合素表达增加两到三倍以及层粘连蛋白产生显著减少。在三维器官型培养中,抗FR细胞内抗体转染的IGROV1细胞呈单层有序生长,类似于体内正常OSE的生长。总之,抗FR细胞内抗体可逆转卵巢癌细胞的转化表型,并可能提供一种有效手段来选择性抑制这些细胞的生长。